No abstract

No abstract

Thirty-two hypertensive patients (mean age 52.9 ± 1.7 years) with a supine diastolic blood pressure (DBP) between 95 and 130 mm Hg (mean 104.3 ± 0.8) received, following a randomized allocation, either tertatolol 5 mg (n = 16) or acebutolol 400 mg (n = 16) in a single daily dose. The 2 drugs were administered during a 3-month treatment period (from day 0 to day 90) in a single-blind fashion. At rest (n = 32), the decrease of supine systolic blood pressure (SBP) reached 27.3 mm Hg after 1 month of tertatolol treatment (from day 0 to day 30; p < 0.01); there was a further decrease of 5.1 mm Hg from day 30 (D30) to day 90 (D90) (NS). The corresponding decreases after acebutolol treatment reached respectively 22.3 mm Hg (p < 0.01) and 5.7 mm Hg (p < 0.05). Similar results were observed in the upright position. The decrease of supine DBP reached 14.0 mm Hg in patients treated with tertatolol from D0 to D30 (p < 0.01); a further decrease of 2.9 mm Hg occurred from D30 to D90 (NS). The corresponding decreases in patients administered acebutolol reached respectively 7.6 mm Hg (p < 0.01) and 5.2 mm Hg (p < 0.01). Similar results were observed in the upright position. On submaximal exercise (ergometric bicycle; n = 18), the decrease of SBP reached respectively 31.3 mm Hg during tertatolol treatment from D0 to D30 (p < 0.01) and 8.8 mm Hg from D30 to D90 (NS). The corresponding decreases during acebutolol treatment reached respectively 29.4 mm Hg (p < 0.01) and 7.1 mm Hg (NS). The decreases of DBP reached 8.2 mm Hg (p < 0.01) and 3.3 mm Hg (NS) during tertatolol administration and 6.3 mm Hg (p < 0.05) and 5.0 mm Hg (p < 0.05) during acebutolol administration. At D90, supine DBP was controlled (≤ 90 mm Hg) in 62.5% of the patients treated with tertatolol and 56.3% in the patients treated with acebutolol. The clinical acceptability of both drugs was satisfactory, and there was no significant change of any of the biochemical parameters. We conclude that the antihypertensive effects of tertatolol 5 mg are efficient, comparable in intensity to those of acebutolol 400 mg, but of earlier onset. This efficacy, combined with a satisfactory clinical and biological acceptability, confirms the role of tertatolol 5 mg in the treatment of sustained essential hypertension.

No abstract

No abstract